Prompt Identification and Management of Severe Hypoglycemia in a Phase III Diabetes Trial

Why This Case Matters

Severe hypoglycemia remains one of the most clinically significant safety risks in diabetes trials, particularly during fasting bioavailability/bioequivalence (BA/BE) studies. This case highlights how timely medical judgment, vigilant monitoring, and adaptive decision-making can prevent escalation, protect participants, and strengthen clinical trial protocols.

Background

BA/BE studies involving antidiabetic agents are inherently high-risk due to altered pharmacokinetics under fasting conditions. In real-world trial settings—especially in India—challenges such as variable site reporting practices and limited access to advanced monitoring tools can delay intervention. This case reflects the importance of proactive pharmacovigilance and medical monitoring aligned with ICH-GCP, CDSCO, and Pharmacovigilance Programme of India (PvPI) expectations.

The Case

A 54-year-old male participant with a 10-year history of Type 2 diabetes mellitus, well controlled on metformin, was enrolled in a Phase III crossover BA/BE study. His baseline HbA1c was 7.2%, with no recent history of hypoglycemic episodes.

Following an overnight fast, the subject received a single 10 mg dose of the investigational product. Four hours post-dose, during routine pharmacokinetic sampling, he reported dizziness, sweating, and confusion. A capillary blood glucose measurement revealed a value of 43 mg/dL, meeting criteria for a serious adverse event.

Immediate Action

The site team promptly administered 15 g of oral glucose as per protocol. Blood glucose levels normalized within 30 minutes. The subject was admitted for overnight observation, during which ECG and laboratory investigations remained within normal limits.

Assessment And Reporting

Causality assessment using WHO–UMC criteria classified the event as probable. The SAE was documented in ALCOA-compliant source records and reported to the sponsor and Ethics Committee within 24 hours in accordance with ICH-GCP and CDSCO timelines.

Outcome And Protocol Impact

The subject recovered fully with no recurrence at 30-day follow-up. A safety signal was identified in 2 out of 32 participants, leading to protocol amendments including mandatory pre-dose glucose assessments and reduced fasting duration.

Doctor's Perspective

This case reinforced that pharmacovigilance is an active clinical responsibility. Early symptom recognition and timely decision-making can significantly alter outcomes and improve participant safety.

Takeaway Note

In clinical trials, safety is not secured by protocols alone—it is secured by timely clinical judgment, vigilant monitoring, and the willingness to adapt when early warning signs appear.